uterine neoplasms/tyrosine

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 16 rezilta yo

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3% to 7% of non-small-cell lung cancers (NSCLCs). Patients harboring ALK rearrangements show very favourable outcomes if treated with targeted agents, among which crizotinib is the first and best studied. Crizotinib, an oral

ALK-rearranged Tumors are Highly Enriched in the STUMP Subcategory of Uterine Tumors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Smooth muscle tumor of uncertain malignant potential (STUMP) is a rare diagnosis rendered when there is uncertainty concerning the biological potential of a smooth muscle tumor. The initial differential diagnosis is often broad, as tumors in this subgroup are morphologically heterogenous. Recent

[Treatment monitoring of patients with uterine cancer with and without progression by free serum amino acids].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We determined 10 free serum amino acids by automatic chromatographic analyses in continuous steps in tumour monitoring of 51 patients with cancer of the uterine body. There were 39 patients without and 12 patients with recurrent disease. We found an elevation of aspartic acid, glutaminic acid,

Phytoestrogens as cardioprotective agents.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Epidemiologic studies have shown that women with a higher dietary intake of phytoestrogens, plant-derived compounds with partial estrogen agonist properties, have a lower incidence of cardiovascular disease and breast and uterine cancer than women with a lower dietary intake of these substances. The

PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Protein Tyrosine Phosphatase H1/Protein Tyrosine Phosphatase Non receptor Type 3 (PTPH1/PTPN3) is upregulated and/or mutated in glioma, ovarian, gastric, and colorectal cancers. Previous studies have documented that PTPH1-associated breast cancers exhibit enhanced sensitivity to tamoxifen and

Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Recent data indicate that insulin-like growth factor I (IGF-I) may have a function in mediating the mitogenic effects of 17beta-estradiol (E2) in the uterus and in regulating the growth of uterine neoplasms. This study was designed to determine whether synthetic and plant-derived chemicals that

Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Fibroblast growth factor receptor 2 (FGFR2) is a membrane-spanning tyrosine kinase that mediates signaling for FGFs. Recent studies detected various point mutations of FGFR2 in multiple types of cancers, including breast cancer, lung cancer, gastric cancer, uterine cancer and ovarian cancer, yet the

Imatinib mesylate and its potential implications for gynecologic cancers.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Among gynecologic malignancies, ovarian carcinoma is the most frequent cause of death, with the majority of patients presenting at advanced stage. There is a high rate of recurrence despite first-line chemotherapy. Sarcoma of the uterus, while accounting for a small percent of uterine cancers, is

Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor β, RET and KIT. Cellular immunotherapy has the potential to be a highly targeted treatment, with low

The EphA2 and cancer connection: potential for immune-based interventions

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The Eph (erythropoietin-producing human hepatocellular) receptors form the largest known subfamily of receptor tyrosine kinases. These receptors interact with membrane-bound ephrin ligands via direct cell-cell interactions resulting in bi-directional activation of signal pathways. Importantly, the

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Uterine serous carcinomas (USCs) are an aggressive form of uterine cancer that may rely on HER2/neu amplification as a driver of proliferation. The objective of this paper is to assess the sensitivity of USC cell lines with and without HER2/neu gene amplification to afatinib, an

Temporal analysis of E2 transcriptional induction of PTP and MKP and downregulation of IGF-I pathway key components in the mouse uterus.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

17beta-Estradiol (E2) is well known to be associated with uterine cancer, endometriosis, and leiomyomas. Although insulin-like growth factor I (IGF-I) has been identified as a mediator of the uterotrophic effect of E2 in several studies, this mechanism is still not well understood. In the present

PDGFRA mRNA overexpression is associated with regional metastasis and reduced survival in oral squamous cell carcinoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Platelet-derived growth factor alpha (PDGFRA) is a gene encoding tyrosine kinase receptor and both EGFR and PDGFRA activate tyrosine kinases. The implication of PGFRA in many cancers and its prognostic significance irrespective to EGFR status in spinal chordoma, gliomas, and uterine

Potential Therapeutic Targets in Uterine Sarcomas.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Uterine sarcomas are rare tumors accounting for 3,4% of all uterine cancers. Even after radical hysterectomy, most patients relapse or present with distant metastases. The very limited clinical benefit of adjuvant cytotoxic treatments is reflected by high mortality rates, emphasizing the need for

The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The proto-oncogene c-kit encodes for a 145-kDa transmembrane tyrosine kinase receptor. Interaction with its ligand, stem cell factor, is essential in the development of hematopoietic stem cells, mast cells, gametocytes, melanocytes, and interstitial cells of Cajal. C-kit expression has

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye